Roche's quarterly released last week indicated Tamiflu sales in Japan of AUD$73 million. Based on Lani having a slight market lead, we'd get around $3 million in royalties.
It's interesting to note Tamiflu was Roche's 5th best revenue generator worldwide for the quarter. Not bad for a mature product.
tamiflu potential dud?, page-19
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)